Artificial liver support system (ALSS) has been used to treat hepatic failure and has significantly decreased the mortality. TECA hybrid artificial liver support system (TECA-HALSS), which combines the hollow fiber bioreactor with a plasma exchange circuit, was used to assess the efficacy, safety and feasibility in treating severe hepatitis patients. The hybrid artificial liver support system (HALSS) consists of a bioreactor containing more than 5 ×109 porcine hepatocytes and plasma exchange device. Fifteen patients with severe hepatitis were treated with this hybrid system. All patients experienced a reduction in symptoms such as fatigue, abdominal distention or ascites. After each treatment serum total bilirubin decreased markedly while prothrombin activity increased. There were ten patients whose progress of hepatocyte necrosis was stopped after HALSS treatment, and finally they recovered completely. One patient received liver transplantation after HALSS therapy and survived. No serious adverse events were noted in the fifteen patients.
OstapowiczG., LeeW.M.Acute hepatic failure: a Western perspective. J Gastroenterol Hepatol2000; 15: 480–8.
4.
Van HoekB., De BoerJ., BoudjemaK.Auxiliary versus orthotopic liver transplantation for acute liver failure. EURALT Study Group. European Auxiliary Liver Transplant Registry. J Hepatol1999; 30: 699–705.
5.
MiwaS., HashikuraY., MitaA.Living-related liver transplantation for patients with fulminant and subfulminant hepatic failure. Hepatology1999; 30: 1521–6.
6.
FriedmanA.L.Why bioartificial liver support remains the holy grail. ASAIO J1998; 44: 241–3.
7.
AbounaG.M., GangulyP.K., HamdyH.M.Extracorporeal liver perfusion system for successful hepatic support pending liver regeneration or liver transplantation: a pre-clinical controlled trial. Transplantation1999; 67: 1576–83.
8.
UchinoJ., MatsushitaM.Artificial liver: strategies for the rescue of patients with liver failure. ASAIO J1994; 40: 74–7.
9.
TakahashiT., MalcheskyP.S., NoseY.Artificial liver: state of the art. Dig Dis Sci1991; 36: 1327–40.
10.
MarxU., BushnaqH., YalcinE.European research and commercialization activities in the field of tissue engineering and liver support in world wide competition. Int J Artif Organs1998; 21: 119–26.
NeuzilD.F., RozgaJ., MoscioniA.D.Use of a novel bioartificial liver in a patient with acute liver insufficiency. Surg1993; 113: 340–3.
13.
WatanabeF.D., MullonC.J., HewittW.R.Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg1997; 225: 484–91.
14.
LanjuanL., QianY., JianrongH.Severe hepatitis treated with an artificial liver support system. Int J Artif Organs2001; 24: 297–303.
15.
LiL.J., YangQ., HuangJ.R.Treatment of hepatic failure with artificial liver support system. Chin Med J2001; 114: 941–5.
16.
StrainA.J., NeubergerJ.M.A bioartificial liver-state of the art. Science2002; 295: 1005–9.
17.
SamuelD., IchaiP., FerayC.Neurological improvement during bioartificial liver sessions in patients with acute liver failure awaiting transplantation. Transplantation2002; 73: 257–64.
18.
SauerI.M., ObermeyerN., KardassisD.Development of a hybrid liver support system. Ann NY Acad Sci2001; 944: 308–19.
19.
FukudaJ., SakiyamaR., NakazawaK.Mass preparation of primary porcine hepatocytes and the design of a hybrid artificial liver module using spheroid culture for a clinical trial. Int J Artif Organs2001; 24: 799–806.
20.
YamashitaY., ShimadaM., IjimaH.Hybrid-artificial liver support system. Surgery2002; 131(suppl): S334–40.
21.
Cuervas-MonsV., ColasA., RiveraJ.A.In vivo efficacy of a bioartificial liver in improving spontaneous recovery from fulminant hepatic failure: a controlled study in pigs. Transplantation2000; 69: 337–44.
22.
AllenJ.W., HassaneinT., BhatiaS.Advances in bioartificial liver devices. Hepatology2001; 34: 447–53.
SiC.W., ZhangH., WangB.E.Prevention, and cure project of viral hepatitis. Revised Statement 5th National Infectious Disease Meeting, Beijing, 1995. Chin J Infect Dis1995; 13: 241–7.
26.
PatienceC., SwitzerW.M., TakeuchiY.Multiple groups of novel retroviral genomes in pigs and related species. J Virol2001; 75: 2771–5.
27.
SeglenP.O.Preparation of isolated rat liver cells. Methods Cell Biol1976; 13: 29–34.
28.
HowardR.B., PeschL.A.Preparation and partial characterization of intact isolated parenchymal cells from rat liver. Biol Chem1968; 243: 3105–14.
29.
PitkinZ., MullonC.Evidence of absence of porcine endogenous retrovirus (PERV) infection in patients treated with a bioartificial liver support system. Int J Artif Organs1999; 23: 829–33.
30.
PatienceC., SwitzerW.M., TakeuchiY.Multiple groups of novel retroviral genomes in pigs and related species. J Virol2001; 75: 2771–5.
31.
FalascaE., AdamiV., AstroriG.Porcine endogenous retrovirus does not infect human cells using a bioartificial liver model system. Transplant Proc2001; 33: 1780–1.
32.
KuddusR., PatzerJFII, LopezR.Clinical and laboratory evaluation of the safety of a bioartificial liver assist device for potential transmission of porcine endogenous retrovirus. Transplantation2002; 73: 420–9.
33.
GossJ.A., ShackletonC.R., MaggardM.Liver transplantation for fulminant hepatic failure in the pediatric patient. Arch Surg1998; 133: 839–46.
34.
EsquivelC.O., KeeffeE.B., GarciaG.Resection versus transplantation for hepatocellular carcinoma. J Gastroenterol Hepatol1999; 14(suppl): S37–41.
